The return of Hip Resurfacing - continuing evidence

JointMedica would like to formally congratulate Catherine Van Der Straeten and the International Hip Resurfacing Group for offering the orthopaedic community compelling evidence supporting the value afforded by the Hip Resurfacing procedure.

“Hip resurfacing arthroplasty in young patients: international high-volume centres’ report on the outcome of 11,382
metal-on-metal hip resurfacing arthroplasties in patients ⩽50 years at surgery”


Published September 9, 2020, this landmark paper signifies an extraordinary international collaboration of the worlds foremost Hip Resurfacing enthusiasts.

Reviewing 11,382 Hip resurfacing arthroplasties (HRA) implanted over time by an international group of 27 experienced HRA centres from 13 countries with a particular focus on a challenging group of patients both male and female, ⩽50 years of age. This study aimed to analyse HRA outcomes in this impressive international cohort with a mean follow-up of 7.6 years.

It is important to note the fact that 18 different metal-on-metal (MoM) HRA designs were included in this research. 2 HRA designs, in particular, led to inferior results. Excluding these two devices, the implant survivorship of 11,063 cases was 95% at 10 years and 90% at 22 years

For male patients, implant survivorship was: 99% at 10 years and 92.5% at 21 years. 

In females, implant survivorship was 90% at 10 years and 81.3% at 22 years

The authors note Higher demands for activity and functionality in younger patients make HRA a potential alternative to Total Hip Arthroplasty (THA).

JointMedica is pleased to see continued validation of this valuable treatment option and looks forward to delivering the Polymotion™ HRA to specialist hip surgeons around the world following successful regulatory approvals.


Polymotion™ JointMedica